

# A case of incomplete and refractory Kawasaki disease: Diagnostic and therapeutic challenges

S Mehndiratta,<sup>1</sup> MBBS, DCh, DNB (Pediatrics), MNAMS; K Rajeshwari,<sup>2</sup> MD (Pediatrics);  
A P Dubey,<sup>2</sup> MD (Pediatrics); R Kumar,<sup>2</sup> MD PGT

<sup>1</sup> Department of Pediatrics, Lok Nayak Hospital, New Delhi, India

<sup>2</sup> Department of Pediatrics, Maulana Azad Medical College, New Delhi, India

Corresponding author: S Mehndiratta (drsmehndiratta@gmail.com)

The diagnosis of incomplete Kawasaki disease (KD) – i.e. cases that do not fulfil all the diagnostic criteria – requires a high index of suspicion. We report a case of incomplete KD that was refractory to treatment with intravenous immunoglobulin and subsequently responded to treatment with intravenous methylprednisolone.

S Afr J CH 2014;8(1):37-38. DOI:10.7196/SAJCH.592



Kawasaki disease (KD) is an acute febrile illness with vasculitis involving the medium-sized blood vessels. Its most serious effect is on the coronary arteries.<sup>[1-3]</sup> The incidence of KD appears to be rising on the Indian subcontinent, where it is increasingly being reported.

This increase in reporting may be due to greater awareness of the disease.<sup>[4,5]</sup> Not all cases fulfil all the diagnostic criteria, and these are termed incomplete KD.<sup>[6,7]</sup> We report a case of incomplete KD that was refractory to the recommended standard treatment with intravenous immunoglobulin (IVIG), but responded to treatment with intravenous methylprednisolone. The case highlights the diagnostic and therapeutic challenges posed by incomplete and refractory KD.

## Case report

An 18-month-old boy was brought to hospital with a history of low-grade pyrexia for 5 days and respiratory distress for 2 days. On examination, he was febrile (axillary temperature 39.2°C), irritable and slightly pale. Examination of the respiratory system revealed a few crackles bilaterally. Initial routine laboratory investigations revealed a haemoglobin (Hb) concentration of 7.3 g/dl, a white cell count (WCC) of  $23.4 \times 10^9$  cells/l and a platelet count of  $539 \times 10^9$  cells/l. A provisional diagnosis of pneumonia was made and the patient was treated with intravenous antibiotics (ceftriaxone); however, the fever persisted and he remained irritable. The findings on cerebrospinal fluid examination were normal. After 3 days he developed a non-itchy erythematous rash all over his body. There was no history of joint pain or joint swelling. Urinary tract infection was excluded by routine urinalysis and culture. On day 9, slight swelling of the limbs developed and peeling at the tips of the fingers and toes was noted. The patient also had redness of the tongue and oral mucosa, but there was no conjunctival congestion and no significant lymphadenopathy. He responded only transiently to antipyretic therapy.

Repeat investigations revealed anaemia (Hb 5.6 g/dl), a high WCC ( $25.7 \times 10^9$  cells/l) with thrombocytosis ( $659 \times 10^9$  cells/l), a raised erythrocyte sedimentation rate (56 mm/h) and positive C-reactive protein (40 mg/l). Tests for rheumatoid factor and antinuclear antibodies were negative. Peripheral smear examination revealed dimorphic anaemia. The patient also had hyponatraemia ( $\text{Na}^+$  128 mmol/l) and hypo-albuminaemia (albumin 25 g/l). Echocardiography revealed dilated ostia of the left main coronary artery (0.446 cm in diameter) (Fig. 1).

Owing to persistence of fever spikes up to 39.4°C, exclusion of other diagnoses and supportive laboratory findings, a diagnosis of incomplete KD was made. The patient was given IVIG (2 g/kg over 12 hours) and started on aspirin therapy (100 mg/kg/d in four divided doses). However, his fever persisted even after 48 hours, so IVIG was repeated. Once again there was no response. Because he was refractory to two doses of IVIG, the patient was given methylprednisolone as recommended (30 mg/kg pulse dose).<sup>[6]</sup> The pyrexia abated within 48 hours and the symptoms improved. He was discharged on treatment with aspirin (5 mg/kg/d). On follow-up about 6 months later, he was well, and echocardiography revealed that the coronary artery anomalies had resolved.

## Discussion

The aetiology of KD is unclear. The clinical features, laboratory criteria and epidemiological profile strongly suggest an infectious cause, but despite a battery of investigations, results so far have been inconclusive. A typical case of KD can be diagnosed on the basis of a set of clinical and laboratory criteria and exclusion of other illnesses.<sup>[1-3]</sup> However, it is increasingly being recognised that not all children who subsequently develop complications fulfil the criteria of typical KD. These cases are termed incomplete or atypical KD.<sup>[6,7]</sup> Approximately 10 - 15% of patients with KD fail to respond to treatment with IVIG, which is the standard first-line treatment.



Fig. 1. Echocardiogram showing dilated ostia of the left main coronary artery (arrow).

They have continuing vasculitis and require additional therapy, and are considered to have refractory KD.<sup>[8]</sup>

The exact incidence of incomplete KD is not known, with few cases being reported owing to the lack of diagnostic criteria and the presence of confounding clinical features that may mimic other childhood illnesses. These patients may remain undiagnosed, but they are as vulnerable to cardiac complications as patients with typical KD.<sup>[9]</sup> A diagnostic algorithm based on a combination of clinical and laboratory criteria has been proposed to help diagnose incomplete KD.<sup>[1]</sup> Factors associated with non-response to standard therapy have been described as male gender, hypo-albuminaemia, high aspartate aminotransferase levels and echocardiographic abnormalities at diagnosis.<sup>[10]</sup> Steroid therapy, e.g. intravenous methylprednisolone, is recommended for the treatment of refractory KD.<sup>[6,11,12]</sup> Complications of KD are coronary artery aneurysms, myocardial infarction, and sudden death, especially related to coronary artery involvement. However, studies have demonstrated that children who do not develop coronary anomalies may have prolonged endothelial dysfunction and abnormal lipid profiles on follow-up.<sup>[13]</sup> Newer therapeutic modalities that have been described, particularly for the treatment of refractory cases, are immunosuppressive agents (methotrexate, cyclophosphamide), infliximab (a chimeric murine/human immunoglobulin G-1 monoclonal antibody that binds specifically to human tumour necrosis factor- $\alpha$ ), and plasma exchange. However, data on their use and success rates are limited.<sup>[14]</sup>

Our patient did not have lymphadenopathy or conjunctivitis, but persistent fever spikes, oedema of the hands and feet with skin peeling, oral mucosal changes and supportive laboratory findings helped to establish the diagnosis using the algorithm proposed for diagnosis of cases that do not fulfil all the criteria for KD.<sup>[1,6,7,15]</sup> Evidence of coronary ostia dilatation on the echocardiogram further supported the diagnosis. Other rheumatological illnesses such as systemic-onset juvenile rheumatoid arthritis (JRA) may have similar nonspecific clinical and laboratory features, and occasionally a case of evolving systemic JRA may mimic atypical KD.<sup>[16]</sup> Many clinical features of KD may mimic other childhood illnesses, and the diagnosis may be missed altogether or the case diagnosed late. The problem may be compounded by certain atypical presentations of KD such as associated hypertension, nephritis or seizures. However, awareness and the rate of diagnosis of the disease have increased in India over the past few years.<sup>[3-5]</sup>

In conclusion, the diagnosis and treatment of incomplete KD pose many challenges for the clinician. Since echocardiographic

anomalies may not develop until 10 days into the illness, the decision to diagnose and treat early based only on clinical suspicion and nonspecific laboratory features may be problematic.

## References

1. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment and long-term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young. *Circulation* 2004;110(17):2747-2771. [<http://dx.doi.org/10.1161/01.CIR.0000145143.19711.78>]
2. Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease. *Expert Rev Anti Infect Ther* 2010;8(2):197-203. [<http://dx.doi.org/10.1586/eri.09.109>]
3. Consul M, Mishra S, Taneja A. Spectrum of Kawasaki disease. *Indian J Pediatr* 2011;78(4):488-490. [<http://dx.doi.org/10.1007/s12098-010-0356-y>]
4. Kushner HI, Macnee R, Burns JC. Impressions of Kawasaki syndrome in India. *Indian Pediatr* 2006;43(11):939-941.
5. Singh S, Aulakh R, Bhalla AK, et al. Is Kawasaki disease incidence rising in Chandigarh, North India? *Arch Dis Child* 2011;96(2):137-140. [<http://dx.doi.org/10.1136/adc.2010.194001>]
6. Parmar RC, Somale A, Bavdekar SB, Muranjan MN. Incomplete Kawasaki disease with recurrent skin peeling: A case report with the review of literature. *J Postgrad Med* 2003;49(1):72-74.
7. Witt M, Minich L, Bohnsack J, et al. Kawasaki disease: More patients are being diagnosed who do not meet American Heart Association criteria. *Pediatrics* 1999;104(1):e10. [<http://dx.doi.org/10.1542/peds.104.1.e10>]
8. Freeman AF, Shulman ST. Refractory Kawasaki disease. *Pediatr Infect Dis J* 2004;23(5):463-464. [<http://dx.doi.org/10.1097/01.inf.0000125893.66941.e0>]
9. Baumer JH. Kawasaki disease: What to do with incomplete cases? *Arch Dis Child Educ Pract Ed* 2005;90(4):ep102-ep104. [<http://dx.doi.org/10.1136/adc.2005.088179>]
10. Ashouri N, Takahashi M, Dorey F, Mason W. Risk factors for non response to therapy in Kawasaki disease. *J Pediatr* 2008;153(3):365-368. [<http://dx.doi.org/10.1016/j.jpeds.2008.03.014>]
11. Brogan PA, Bose A, Burgner D, et al. Kawasaki disease: An evidence based approach to diagnosis, treatment, and proposals for future research. *Arch Dis Child* 2002;86(4):286-290. [<http://dx.doi.org/10.1136/adc.86.4.286>]
12. Newburger JW, Fulton DR. Kawasaki disease. *Current treatment Options in Cardiovascular Medicine* 2007;9(2):148-158. [<http://dx.doi.org/10.1007/s11936-007-0008-3>]
13. McCrindle BW. Cardiovascular complications – coronary artery structure and function. *Progress Pediatric Cardiol* 2004;19(2):147-152. [<http://dx.doi.org/10.1016/j.ppedcard.2004.08.008>]
14. Rowley AH, Shulman ST. Recent advances in the understanding and management of Kawasaki disease. *Curr Infect Dis Rep* 2010;12(2):96-102. [<http://dx.doi.org/10.1007/s11908-010-0091-6>]
15. Kurutobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. *Pediatr Int* 2002;44(1):1-4. [<http://dx.doi.org/10.1046/j.1442-200X.2002.01508.x>]
16. Shaikh S, Ishaque S, Saleem T. Incomplete, atypical Kawasaki disease or evolving systemic juvenile idiopathic arthritis: A case report. *Cases J* 2009;2(1):6962. [<http://dx.doi.org/10.4076/1757-1626-2-6962>]